{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:19:19Z","timestamp":1791317959780,"version":"4.3.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Angiotensin converting enzyme (ACE) inhibitor therapy does not reliably suppress aldosterone production, and \u2018aldosterone escape\u2019 occurs in up to 40% of patients with congestive heart failure (CHF). Aldosterone levels correlate with the risk of cardiovascular events. Aldosterone adversely affects the risk of cardiovascular events via mineralocorticoid receptors in the heart, blood vessels and other sites. Notably, aldosterone contributes to endothelial dysfunction and attenuates endothelium-dependent vasodilatation, at least partly by reducing nitric oxide bioavailability. Aldosterone also promotes myocardial fibrosis and cardiac remodelling by enhancing collagen synthesis, resulting in increased myocardial stiffness and increased left ventricular mass. These mechanisms mediated by aldosterone contribute to increased risk of ventricular arrhythmias and sudden cardiac death. Two major prospective trials, including one in which patients routinely received ACE inhibitor and beta blocker therapy, have shown that the use of an aldosterone blocker significantly reduces all-cause mortality, sudden cardiovascular death and hospitalisation in patients with acute or chronic left ventricular dysfunction or CHF. Inhibition of aldosterone's effect on mineralocorticoid receptors should now be considered standard therapy in these patient populations.<\/jats:p>","DOI":"10.1016\/j.ejheart.2004.04.013","type":"journal-article","created":{"date-parts":[[2004,9,27]],"date-time":"2004-09-27T16:07:09Z","timestamp":1096301229000},"page":"539-545","source":"Crossref","is-referenced-by-count":112,"title":["The Clinical Implications of Aldosterone Escape in Congestive Heart Failure"],"prefix":"10.1093","volume":"6","author":[{"given":"Allan D.","family":"Struthers","sequence":"first","affiliation":[{"name":"Division of Medicine and Therapeutics, Ninewells Hospital and Medical School , Dundee, DD1 9SY ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2004,9,27]]},"reference":[{"key":"2026020204003107700_ejhf2004-04-013-bib-0001","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0002","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/hrt.82.1.57","article-title":"How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure=","volume":"82","author":"MacFadyen","year":"1999","journal-title":"Heart"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0003","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/147323000102900103","article-title":"Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy","volume":"29","author":"Sato","year":"2001","journal-title":"J Int Med Res"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0004","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1136\/hrt.52.5.530","article-title":"Captopril in heart failure: a double blind controlled trial","volume":"52","author":"Cleland","year":"1984","journal-title":"Br Heart J"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0005","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/j.1552-4604.1993.tb03901.x","article-title":"Evidence of a partial escape of renin\u2013angiotensin\u2013aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors","volume":"33","author":"Borghi","year":"1993","journal-title":"J Clin Pharmacol"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0006","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/147323000102900103","article-title":"Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy","volume":"29","author":"Sato","year":"2001","journal-title":"J Int Med Res"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0007","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0008","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1388-9842(99)00046-X","article-title":"Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study","volume":"1","author":"Lee","year":"1999","journal-title":"Eur J Heart Fail"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0009","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium and myocardial fibrosis","volume":"120","author":"Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/euhj.1999.1740","article-title":"Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure","volume":"21","author":"Roig","year":"2002","journal-title":"Eur Heart J"},{"issue":"Suppl N","key":"2026020204003107700_ejhf2004-04-013-bib-0011","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/eurheartj\/16.suppl_N.79","article-title":"Mechanisms of angiotensin II formation in humans","volume":"16","author":"Urata","year":"1995","journal-title":"Eur Heart J"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0012","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1677\/jme.0.0240321","article-title":"Expression of 11\u00df-hydroxylase and aldosterone synthase genes in the rat brain","volume":"24","author":"MacKenzie","year":"2000","journal-title":"J Mol Endocrinol"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0013","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0014","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0016","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1053\/euhj.1998.1093","article-title":"Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study","volume":"19","author":"Vantrimpont","year":"1998","journal-title":"Eur Heart J"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0017","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0002-9149(01)02261-5","article-title":"Relation of aldosterone \u2018escape\u2019 despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy","volume":"89","author":"Cicoira","year":"2002","journal-title":"Am J Cardiol"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0018","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1053\/euhj.1998.1099","article-title":"Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients","volume":"19","author":"Duprez","year":"1998","journal-title":"Eur Heart J"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0019","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0002-9149(94)90362-X","article-title":"The association of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study)","volume":"74","author":"Tsuji","year":"1994","journal-title":"Am J Cardiol"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0020","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0735-1097(10)80329-8","article-title":"Prognostic importance of the serum magnesium concentration in patients with congestive heart failure","volume":"16","author":"Gottlieb","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0021","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1161\/hc4601.099485","article-title":"Endothelial dysfunction, oxidative stress and risk of cardiovascular events in patients with coronary artery disease","volume":"104","author":"Heitzer","year":"2001","journal-title":"Circulation"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0022","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/cs1030425","article-title":"Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy","volume":"103","author":"Farquharson","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0023","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0922-4106(95)90018-7","article-title":"Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induce by interleukin-1\u00df","volume":"290","author":"Ikeda","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0024","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0735-1097(01)01729-6","article-title":"Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression","volume":"39","author":"Bauersachs","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0025","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0026","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","article-title":"Mineralocorticoid receptor antagonism in experimental atherosclerosis","volume":"105","author":"Rajogopalan","year":"2002","journal-title":"Circulation"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0027","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","article-title":"Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease","volume":"76","author":"Barr","year":"1995","journal-title":"Am J Cardiol"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0028","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1006\/jmcc.1994.1098","article-title":"Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone","volume":"26","author":"Brilla","year":"1994","journal-title":"J Mol Cell Cardiol"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0029","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.RES.67.6.1355","article-title":"Remodeling of the rat right and left ventricles in experimental hypertension","volume":"67","author":"Brilla","year":"1990","journal-title":"Circ Res"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0030","doi-asserted-by":"crossref","first-page":"94A","DOI":"10.1016\/S0895-7061(97)91058-X","article-title":"Effects of the selective mineralocorticoid receptor antagonist, eplerenone, in a model of aldosterone-induced hypertension and cardiac fibrosis","volume":"11","author":"Frierdich","year":"1998","journal-title":"Am J Hypertens"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0031","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1161\/01.CIR.0000039104.56479.42","article-title":"Long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure","volume":"106","author":"Suzuki","year":"2002","journal-title":"Circulation"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0032","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0008-6363(97)00091-6","article-title":"Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients","volume":"35","author":"MacFadyen","year":"1997","journal-title":"Cardiovasc Res"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0033","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/01.HYP.0000023182.68420.EB","article-title":"Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism","volume":"40","author":"Rossi","year":"2002","journal-title":"Hypertension"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0034","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mhj.2001.111258","article-title":"Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction","volume":"141","author":"Modena","year":"2001","journal-title":"Am J Heart"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1291\/hypres.22.17","article-title":"Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension","volume":"22","author":"Sato","year":"1999","journal-title":"Hypertens Res"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0036","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s00059-003-2511-y","article-title":"A neuroendocrine\u2013immune interface. The immunostimulatory state of aldosteronism","volume":"28","author":"Weber","year":"2003","journal-title":"Herz"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0037","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/01.HYP.19.3.270","article-title":"Aldosterone reduces baroreceptor discharge in the dog","volume":"19","author":"Wang","year":"1992","journal-title":"Hypertension"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0038","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/01.HYP.24.5.571","article-title":"Chronic administration of aldosterone depresses baroreceptor reflex function in the dog","volume":"24","author":"Wang","year":"1994","journal-title":"Hypertension"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0039","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1042\/cs0950687","article-title":"Aldosterone blunts the baroreflex response in man","volume":"95","author":"Yee","year":"1998","journal-title":"Clin Sci"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0040","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0041","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"2026020204003107700_ejhf2004-04-013-bib-0042","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ejheart.2004.04.013","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/6\/5\/539\/66649293\/eurjhf_6_5_539.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/6\/5\/539\/66649293\/eurjhf_6_5_539.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T09:00:41Z","timestamp":1770022841000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/6\/5\/539\/8446684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,1]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2004,9,27]]},"published-print":{"date-parts":[[2004,8,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ejheart.2004.04.013","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2004,8]]},"published":{"date-parts":[[2004,8,1]]}}}